Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | GPR4 | P46093 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825768 | 0.95 | HRH2 (0.56) | HRH2HRH1KCNA5DRD3RAB9A | |
| SCHEMBL22609232 | 0.94 | GPR4 (0.57) | HRH2HRH1KCNA5DRD3RAB9A | |
| SCHEMBL15300688 | 0.94 | HRH2 (0.69) | HRH2HRH1RAB9AEPHX2DRD2 | |
| SCHEMBL20075945 | 0.90 | HRH2 (0.52) | HRH2HRH1KCNA5DRD3RAB9A | |
| SCHEMBL19479118 | 0.89 | DRD3 (0.70) | HRH2HRH1KCNA5DRD3DRD2 | |
| SCHEMBL20423457 | 0.89 | DRD3 (0.55) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL14453585 | 0.89 | KCNA5 (0.62) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL23301374 | 0.88 | DRD3 (0.54) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL14453658 | 0.88 | DRD3 (0.54) | HRH2HRH1KCNA5DRD3EPHX2 | |
| SCHEMBL1730771 | 0.88 | HRH2 (0.58) | HRH2HRH1KCNA5DRD3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2024-05-16 | — | — | US | disclosed |
| EP-4285996-A2 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220315585-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2022-10-06 | — | — | US | disclosed |
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | HRH2 3396/4885HRH1 2474/4885KCNA5 3119/4885 |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | HRH2 3396/4885HRH1 2474/4885KCNA5 3119/4885 |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | HRH2 3396/4885HRH1 2474/4885KCNA5 3119/4885 |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | HRH2 3396/4885HRH1 2474/4885KCNA5 3119/4885 |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | HRH2 3185/4885HRH1 2367/4885KCNA5 2684/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | HRH2 2033/4885HRH1 1274/4885KCNA5 2198/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | HRH2 586/4885HRH1 363/4885KCNA5 1588/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | HRH2 3396/4885HRH1 2474/4885KCNA5 3119/4885 |
| US-20220315585-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | HRH2 3396/4885HRH1 2474/4885KCNA5 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.